Last reviewed · How we verify
NCT05232279
Effect of Testofen on Erectile Function in an Adult Male Population - A Double Blind, Randomised Controlled Trial.
Phase 3 trial testing Testofen 300mg in Erectile Dysfunction in 120 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | RDC Clinical Pty Ltd |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 19 April 2022 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Testofen 300mg — full drug profile →
- Testofen 600mg — full drug profile →
- Placebo comparator
Conditions studied
- Erectile Dysfunction — all drugs for Erectile Dysfunction →
Sponsor
RDC Clinical Pty Ltd — full company profile →
Who can join
Adults 40 to 75, male only, with Erectile Dysfunction. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Change in International Index of Erectile Function (IIEF) questionnaire
Time frame: Baseline prior to commencement of study product, Week 4, Week 8 and Week 12
The IIEF is a self-administered questionnaire in which participants will be asked to answer 15 questions relating to erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall sexual satisfaction. Lower scores indicated higher perceived erectile dysfunction -
Change in Erection Hardness Score (EHS)
Time frame: Baseline prior to commencement of study product, Week 4, Week 8 and Week 12
Participants will be required to assess their erection quality by using the EHS. They will be asked to rate the hardness of their erection on a scale of one to four, with four being the maximal score.
Sponsor's own description
This is a double blind, randomised, placebo-controlled clinical study with a 12-week participation and 3 groups (2 active groups and 1 placebo group) designed to monitor erectile function symptom severity and the effect Testofen may have on improving erectile function, sexual function, and quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05232279
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Erectile Dysfunction
Currently open trials in the same condition.
- NCT07442396 — The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation · NA · recruiting
- NCT07366970 — Is There a Benefit From Addition of Exercise in Diabetic Patients With ED Who Complain Low Vitamin D? · NA · recruiting
- NCT06960746 — Changing Lifestyle in OSA Males Who Suffer Metabolic Syndrome and Impotence: Is There a Response? · NA · recruiting
- NCT06872866 — The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under · Phase 1 · recruiting
- NCT06805513 — Actual Use Trial of Tadalafil 5 mg · Phase 3 · recruiting
Other RDC Clinical Pty Ltd trials
Trials by the same sponsor.
- NCT06878001 — CaroRite™ for Skin Health and Signs of Ageing · Phase 4 · completed
- NCT06907680 — M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis · Phase 2 · completed
- NCT06837961 — LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases · Phase 3 · completed
- NCT06827327 — LC-Plasma for Preventing URTIs and Reducing Symptoms · Phase 3 · completed
- NCT06840080 — OEA and LipiSperse Metabolic Study · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05232279 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RDC Clinical Pty Ltd
- Last refreshed: 21 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05232279.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing